Apolipoprotein E e4 allele status and later-life depression in the Lothian Birth Cohort 1936.
Apolipoprotein E e4 allele status and later-life depression in the Lothian Birth Cohort 1936.
复制标题
DOI：
10.1017/s0033291721000623
复制
发表时间：
2021-03-02
影响因子：
6.9
通讯作者：
McIntosh, Andrew M.
中科院分区：
文献类型：
--
作者：
Iveson, Matthew H.;Taylor, Adele;Harris, Sarah E.;Deary, Ian J.;McIntosh, Andrew M.
关于载脂蛋白E e4(ApoE E4)等位基因在晚年抑郁症中的作用，以前的结果褒贬不一：一些研究指出，携带者症状更严重，风险更高，而其他研究发现没有这种联系。然而，很少有前瞻性的、基于人群的apoe e4-抑郁症相关性研究，也很少有纵向研究抑郁症症状轨迹和抑郁风险的研究。我们在12年的随访期中研究了载脂蛋白E e4等位基因状态与抑郁症状和老年抑郁风险的纵向变化之间的关系。我们使用了来自1936年洛锡安出生队列的690名参与者的数据，这些参与者参加了1947年的苏格兰心理调查(11岁)，并在2004年至2019年的五次浪潮中进行了后续跟踪(年龄70-82岁)。我们使用APOE e4等位基因状态来预测抑郁症状评分和抑郁风险(通过症状评分阈值或抑郁相关药物的使用来定义)的纵向变化。模型根据性别、儿童认知能力、儿童社会阶层、教育程度、成人社会阶层、吸烟状况和功能限制进行了基线调整。抑郁症状评分随年龄增长而增加。一旦调整了协变量，APOE e4等位基因状态并不能显著预测症状评分轨迹或抑郁风险。基线时功能限制越大，症状评分轨迹越差，抑郁风险就越高(由药物定义)。ApoE e4等位基因状态不会显著降低性别、教育程度或功能限制的影响。没有证据表明apoe e4携带者患老年抑郁症的风险增加。
Previous results have been mixed regarding the role of the apolipoprotein E e4 (APOE e4) allele in later-life depression: some studies note that carriers experience greater symptoms and increased risk while others find no such association. However, there are few prospective, population-based studies of the APOE e4-depression association and fewer that examine depressive symptom trajectory and depression risk longitudinally. We examined the association between APOE e4 allele status and longitudinal change in depressive symptoms and depression risk in later-life, over a 12-year follow-up period. We used data from 690 participants of the Lothian Birth Cohort 1936 who took part in the Scottish Mental Survey 1947 (aged 11) and were followed-up in later-life over five waves from 2004 to 2019 (aged 70–82). We used APOE e4 allele status to predict longitudinal change in depressive symptom scores and risk of depression (defined by a symptom score threshold or use of depression-related medication). Models were adjusted for sex, childhood cognitive ability, childhood social class, education, adult social class, smoking status and functional limitations at baseline. Depressive symptom scores increased with age. Once adjusted for covariates, APOE e4 allele status did not significantly predict symptom score trajectories or depression risk. Greater functional limitations at baseline significantly predicted poorer symptom score trajectories and increased depression risk (defined by medications). APOE e4 allele status did not significantly moderate the contribution of sex, education or functional limitations. There was no evidence that APOE e4 carriers experience an increased risk for later-life depression.